Cargando…

Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma

Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, Jingjing, Fan, Zhe, Zhang, Yewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755348/
https://www.ncbi.nlm.nih.gov/pubmed/33376710
http://dx.doi.org/10.2147/JHC.S272762
_version_ 1783626335771426816
author Zong, Jingjing
Fan, Zhe
Zhang, Yewei
author_facet Zong, Jingjing
Fan, Zhe
Zhang, Yewei
author_sort Zong, Jingjing
collection PubMed
description Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanced stage or have established distant metastases. The treatment of HCC is limited, with poor prognosis and short natural survival time. In order to improve the efficiency of early diagnosis, it is particularly significant to choose economic and effective diagnosis methods. Ultrasound, magnetic resonance imaging, and computed tomography are usually used in the clinic, but these methods are extremely limited in the diagnosis of HCC. Tumor markers have become the main effective early clinical diagnosis method. Potential serum tumor markers include alpha fetoprotein heterogeneity, Golgi protein 73, phosphatidylinositol proteoglycan (GPC-3), osteopontin, abnormal prothrombin, and heat shock protein. These tumor markers provide new ideas and methods for the diagnosis of HCC. A combination of multiple markers can make up for the deficiency of single marker detection and provide a new strategy for the prognosis and auxiliary diagnosis of HCC. This review introduces protein tumor markers utilized over the past five years.
format Online
Article
Text
id pubmed-7755348
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77553482020-12-28 Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma Zong, Jingjing Fan, Zhe Zhang, Yewei J Hepatocell Carcinoma Review Primary hepatocellular carcinoma (HCC) is one of the most frequently occurring pernicious tumors in the world. It is typically very insidious in the early stages with no obvious symptoms. Its development and metastasis are very rapid. Upon diagnosis, most patients have already reached a local advanced stage or have established distant metastases. The treatment of HCC is limited, with poor prognosis and short natural survival time. In order to improve the efficiency of early diagnosis, it is particularly significant to choose economic and effective diagnosis methods. Ultrasound, magnetic resonance imaging, and computed tomography are usually used in the clinic, but these methods are extremely limited in the diagnosis of HCC. Tumor markers have become the main effective early clinical diagnosis method. Potential serum tumor markers include alpha fetoprotein heterogeneity, Golgi protein 73, phosphatidylinositol proteoglycan (GPC-3), osteopontin, abnormal prothrombin, and heat shock protein. These tumor markers provide new ideas and methods for the diagnosis of HCC. A combination of multiple markers can make up for the deficiency of single marker detection and provide a new strategy for the prognosis and auxiliary diagnosis of HCC. This review introduces protein tumor markers utilized over the past five years. Dove 2020-12-18 /pmc/articles/PMC7755348/ /pubmed/33376710 http://dx.doi.org/10.2147/JHC.S272762 Text en © 2020 Zong et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zong, Jingjing
Fan, Zhe
Zhang, Yewei
Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
title Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
title_full Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
title_fullStr Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
title_full_unstemmed Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
title_short Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma
title_sort serum tumor markers for early diagnosis of primary hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755348/
https://www.ncbi.nlm.nih.gov/pubmed/33376710
http://dx.doi.org/10.2147/JHC.S272762
work_keys_str_mv AT zongjingjing serumtumormarkersforearlydiagnosisofprimaryhepatocellularcarcinoma
AT fanzhe serumtumormarkersforearlydiagnosisofprimaryhepatocellularcarcinoma
AT zhangyewei serumtumormarkersforearlydiagnosisofprimaryhepatocellularcarcinoma